McKesson Corporation's (NYSE:MCK) Q4 2024 fiscal year results were a mix of strong revenue growth and weaker-than-expected earnings. Despite the mixed financial performance, the company's stock has often outperformed competitors and its five-year return is an impressive 340%. However, some analyst reports suggest caution should be exercised due to unexpected earnings dips. Despite this, McKesson successfully raised full-year guidance, hinting at future growth potential.
McKesson's strategic expansions and new product launches, coupled with a positive outlook for the fiscal year 2025, contributed to notable market performance, including hitting a new all-time high. Yet, quarterly results from the US pharmaceuticals segment weighed in, resulting in missed estimates. On the other hand, the forecasts have been increased following Q4 results, and MCK's intrinsic value is potentially 82% above its share price, signaling undervaluation.
McKesson's institutional ownership exceeds 88%, demonstrating a high level of investor confidence. Lastly, the strong demand for specialty medicines has led McKesson to increase its annual profit forecast.
Mckesson Corporation MCK News Analytics from Mon, 18 Sep 2023 07:00:00 GMT to Thu, 09 May 2024 14:29:41 GMT - Rating 7 - Innovation 6 - Information 8 - Rumor -3
